GenEdit is expanding! 🚀 We're thrilled to announce our move to a larger, state-of-the-art facility at the Genesis-Marina life sciences development in the heart of the South San Francisco biotech hub. We are incredibly grateful to Eli Lilly and Company for their support during our time at the Lilly Gateway Labs and are excited about our new home with the space and resources to accelerate our growth and innovation. We can't wait to welcome you and continue pushing the boundaries of what's possible in the life sciences! #GenEdit #NewHQ #GenesisMarina #LifeSciences #SouthSanFrancisco #Biotech #Growth #Innovation
GenEdit
Biotechnology Research
South San Francisco, California 2,684 followers
Delivering the potential of genetic medicines
Über uns
GenEdit is focused on overcoming the major challenge to genetic medicines: Delivery. We aim to overcome this limitation and enable treatment of a broad range of diseases, having a positive impact on the lives of as many people as possible. The foundation of our company is our NanoGalaxy platform. NanoGalaxy contains a library spanning thousands of unique non-viral, non-lipid, polymer nanoparticles. Using our iterative screening process, we are able to identify polymer nanoparticles that can deliver the needed genetic medicine payload to the needed tissue to treat disease. We are focusing our research on the treatment of diseases for which our delivery technology can enable therapeutic options that otherwise may not be possible. We are developing an internal pipeline of therapeutic candidates to treat a range of diseases with high unmet medical need.
- Website
-
http://www.GenEdit.com
External link for GenEdit
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 11-50 Mitarbeiter
- Hauptsitz
- South San Francisco, California
- Typ
- In Privatbesitz
- Gegründet
- 2016
Standorte
-
Primäre
Wegbeschreibung erhalten
681 Gateway Blvd
Suite 313
South San Francisco, California 94080, US
Employees at GenEdit
Aktualisierungen
-
Interested in hearing more about Genedit at #BIO2024? I will present GenEdit at the Company Presentation Theater 3 session on Monday June 3rd at 12:45 pm. Let's connect in the BIO One-on-One Partnering system. See you in San Diego.
-
Congratulations to Editas Medicine for the new status of RUBY as a Phase 1/2/3 trial! With the potential to revolutionize treatment for sickle cell anemia patients, Reni-cel represents a significant advancement in medical innovation. This milestone is also exciting for GenEdit because Reni-cel incorporates our cutting-edge technologies licensed to Editas.
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates | Editas Medicine
ir.editasmedicine.com
-
We're excited to announce a collaboration with Genentech to discover and develop novel nanoparticles with our #Nanogalaxy platform to deliver Genentech’s nucleic acid-based medicines for treatment of #autoimmunedisease. Read the release here: https://lnkd.in/gvh8J4T6 #geneticmedicines
GenEdit Announces Multiyear Collaboration and License Agreement with Genentech to Develop Novel Nanoparticles to Deliver Genetic Medicines for Autoimmune Disease
https://genedit.com
-
GenEdit reposted this
We are pleased to announce that the GenEdit team is a Phase I winner of the National Institutes of Health TARGETED Challenge for programmable delivery systems for gene editing. The award is a recognition of the potential of our NanoGalaxy® platform for a broad range of genetic medicines for multiple therapy areas.
Challenge.Gov
challenge.gov
-
We are pleased to announce that the GenEdit team is a Phase I winner of the National Institutes of Health TARGETED Challenge for programmable delivery systems for gene editing. The award is a recognition of the potential of our NanoGalaxy® platform for a broad range of genetic medicines for multiple therapy areas.
Challenge.Gov
challenge.gov